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Abstract
Background: Several decision support systems have been developed to interpret HIV-1 drug resistance genotyping results.
This study compares the ability of the most commonly used systems (ANRS, Rega, and Stanford’s HIVdb) to predict
virological outcome at 12, 24, and 48 weeks.
Methodology/Principal Findings: Included were 3763 treatment-change episodes (TCEs) for which a HIV-1 genotype was
available at the time of changing treatment with at least one follow-up viral load measurement. Genotypic susceptibility
scores for the active regimens were calculated using scores defined by each interpretation system. Using logistic regression,
we determined the association between the genotypic susceptibility score and proportion of TCEs having an undetectable
viral load (,50 copies/ml) at 12 (8–16) weeks (2152 TCEs), 24 (16–32) weeks (2570 TCEs), and 48 (44–52) weeks (1083 TCEs).
The Area under the ROC curve was calculated using a 10-fold cross-validation to compare the different interpretation
systems regarding the sensitivity and specificity for predicting undetectable viral load. The mean genotypic susceptibility
score of the systems was slightly smaller for HIVdb, with 1.9261.17, compared to Rega and ANRS, with 2.2261.09 and
2.2361.05, respectively. However, similar odds ratio’s were found for the association between each-unit increase in
genotypic susceptibility score and undetectable viral load at week 12; 1.6 [95% confidence interval 1.5–1.7] for HIVdb, 1.7
[1.5–1.8] for ANRS, and 1.7 [1.9–1.6] for Rega. Odds ratio’s increased over time, but remained comparable (odds ratio’s
ranging between 1.9–2.1 at 24 weeks and 1.9–2.2 at 48 weeks). The Area under the curve of the ROC did not differ between
the systems at all time points; p=0.60 at week 12, p=0.71 at week 24, and p=0.97 at week 48.
Conclusions/Significance: Three commonly used HIV drug resistance interpretation systems ANRS, Rega and HIVdb predict
virological response at 12, 24, and 48 weeks, after change of treatment to the same extent.
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Introduction
The effectiveness of antiretroviral therapy has been limited by
the development of HIV-1 drug resistance. Resistance occurs
frequently in patients and may decrease both the magnitude and
the duration of the response to treatment [1].
Several prospective studies have shown that the use of genotypic
resistance analysis to guide the new treatment choice for patients
failing their current HAART improves virologic outcome
[2,3,4,5]. The complex mutational patterns are however difficult
to interpret, due to the many different drug resistance mutations
[6] and the varying levels of decreased susceptibility of these
PLoS ONE | www.plosone.org 1 July 2010 | Volume 5 | Issue 7 | e11505mutations to different drugs. This led to the development of
several interpretation systems [7], which provide rules to help
physicians interpret HIV-1 drug resistance genotyping results.
ANRS, Stanford HIVdb, and Rega are the three most
commonly used and publicly available drug resistance interpreta-
tion systems, which are all regularly updated. The systems are rule
based algorithms, providing scores for specific (combinations of)
mutations. The scores are then translated into different levels of
susceptibility. The rules for these scores are based on literature and
expert’s opinion. The Rega system was the first to be validated in
drug experienced patients [8,9], followed by ANRS [5,9] and
Stanford [9].
A good way to compare systems is by using virological response
data in correlation with the prediction of interpretation systems.
However, some systems may be better for short-term virological
outcomes, and others may be better for longer-term outcomes.
The results of a comparison between systems may therefore
depend on the virological outcome time point that is used. In this
study, a large data set of HIV-1 patient’s sequences was collected
together with virological data to compare the three most
commonly used interpretation systems in genotypic susceptibility
score and in the prediction of virological response. We used 3
different virological outcome time points to analyze the effect of
therapy duration on the prediction of systems.
Methods
Study population
Data was made available through the EU-sponsored ViroLab
and EuResist projects [10,11,12]. The ViroLab project comprises
data from Belgium (Katholieke Universiteit Leuven), Italy
(University of Brescia and Catholic University of the Sacred
Heart of Roma), Spain (IrsiCaixa Badalona), and The Netherlands
(Erasmus Medical Centre Rotterdam). The EuResist project
consists of data from Italy (ARCA database; http://www.
hivarca.net/), Germany (AREVIR database); Sweden (Karolinska
Infectious Diseases and Clinical Virology Department), and
Luxembourg (Retrovirology Laboratory, CRP-Sante ´). The time-
periods of available therapies in the ViroLab and EuResist
database ranged between 1996 and 2008.
These databases were used to extract treatment change episodes
(TCEs). TCEs were defined, in patients aged $18, as follows
(figure 1): (1) a baseline genotype (Reverse transcriptase and
Protease region) and viral load (detectable being .50 copies/ml)
obtained within 90 days before and 8 days after treatment change;
(2) at least one follow-up viral load measurement at 12 (range: 8–
16), 24 (16–32), or 48 (44–52) weeks; (3) no changes in therapy
between the time of the baseline viral load and the follow-up viral
load measurement. In case more genotypic tests or viral load
measurements were performed within an analyzed treatment
period, the value closest to the start of therapy or the follow-up
measurement time was used.
Interpretation systems and genotypic susceptibility
scores (GSSs)
The genotypic results were interpreted using three commonly
used rule-base interpretation systems: Agence Nationale de
recherches sur le SIDA (ANRS) version 17; Stanford HIVdb,
version 5.1.2; and Rega Institute version 8.0.1. The ANRS and
Rega both report 3 levels of resistance: susceptible, intermediate,
and resistant. For ANRS, we translated the definitions ‘suscepti-
ble’, ‘intermediate’, and ‘resistant’ into susceptibility scores of 1,
0.5, and 0, respectively. For the Rega scores, we used the weighted
score suggested by Rega, which uses the following changes:
NNRTI were scored 0.25 (with the exception of etravirine with a
score of 0.5) for intermediate resistance, and ritonavir-boosted PI
were scored 0.75 and 1.5 for intermediate resistance and
susceptible, respectively. The Stanford algorithm uses 5 levels of
resistance. We assigned the following scores to these 5 levels of
Stanford: 0, 0.25, 0.50, 0.75, and 1 for respectively the high-level
resistance, intermediate resistance, low-level resistance, potential
low-level resistance, and susceptible. In a separate analysis we used
the unweighted scores for Rega. We assigned the scores 0, 0.5, and
1 to the ‘resistant’, ‘intermediate’, and ‘susceptible’ groups for all
drugs, respectively. The three systems did not include a score for
ritonavir. We therefore excluded eleven TCEs that used ritonavir
as only protease inhibitor, as we could not calculate a GSS of their
treatment regimens.
The arithmetic sum of the individual score for the specific drugs
provided the total GSS of that treatment. For brevity, we classified
the total GSS score in the following categories: 0 to ,1, 1 to ,2, 2
to ,3, 3 to ,4, and $4. The 0 to ,1 group contains viral
sequences almost entirely resistant to the drugs in their regimen,
and the $4 group contains viral sequences susceptible to more
than 3 drugs given in their regimen.
To calculate the prevalence of drug resistance we used the
mutation list published by the International AIDS Society USA
(IAS-USA) [13].
Statistical analysis
Kaplan-Meier curves were estimated to determine the associ-
ation between GSSs and the proportion of TCEs having an
undetectable viral load (,50 copies/ml). The association between
GSS scores and undetectable viral load was analyzed with a
logistic regression. In the multivariate analyses we adjusted for real
time to viral load measurement (i.e. number of days between the
Figure 1. Schematic definition of a treatment change episode. The treatment change episode requirements are as follows: (1) a baseline
genotypic drug-resistance and viral load test between 90 days before and 8 days after change of therapy (2) at least one follow-up viral load
measurement at 12 (8–16), 24 (16–32), or 48 (44–52) weeks.
doi:10.1371/journal.pone.0011505.g001
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Number of patients 3131
Male, number (%) 272 (72.6)
Age, median (IQR
*) 39 (18–78)
HIV-1 subtype, number (%) Subtype B 2563 (81.9)
Subtype A 158 (5.0)
Subtype G 118 (3.8)
Subtype C 90 (2.9)
other 76 (2.4)
Subtype F 62 (1.9)
CRF 02_AG 28 (0.9)
CRF 12_BF 24 (0.8)
unclassified 12 (0.4)
Number of treatment-change episodes 3763
Baseline CD4 count (cells/mm
3), median (IQR) 233 (120–371)
Baseline viral load (log10)(copies/ml), median (IQR) 4.43 (3.65–5.08)
Number (%)
Treatment-change episodes 1 treatment-change episode 1555 (41.3)
.1 treatment-change episodes 476 (12.6)
.2 treatment-change episodes 108 (2.9)
Year of treatment 1996–2000 649 (17.2)
2001–2004 2085 (55.4)
2005–2008 1029 (27.3)
NRTI Drug treatment lamivudine 2224 (59)
tenofovir 1400 (37)
zidovudine 1082 (29)
didanosine 1007 (27)
stavudine 932 (25)
abacavir 590 (16)
didanosine 653 (18)
emtricitabine 246 (7)
NNRTI Drug treatment efavirenz 660 (18)
nevirapine 447 (12)
etravirine 1 (0)
delavirdine 1 (0)
PI Drug treatment lopinavir 1309 (35)
nelfinavir 332 (9)
atazanavir 274 (7)
indinavir 263 (7)
saquinavir 221 (6)
amprenavir 202 (5)
tipranavir 70 (2)
darunavir 28 (1)
Other drug treatment T20 135 (4)
therapy combinations lamivudine + lopinavir + zidovudine 315 (8)
lamivudine + lopinavir + tenofovir 244 (6)
lamivudine + zidovudine + abacavir 133 (4)
lamivudine + tenofovir + efavirenz 133 (4)
lamivudine + zidovudine + efavirenz 114 (3)
tenofovir + lopinavir + didanosine 102 (3)
*IQR is interquartile range.
doi:10.1371/journal.pone.0011505.t001
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load at start of therapy. Furthermore, we used logistic regression,
to calculate Odds Ratios for each GSS group compared to the
GSS group of 0 to ,1. The receiver operating characteristic
(ROC) curves were calculated to analyze the trade-off between the
proportion of true-positive (correct virologic response prediction)
and false-positive (incorrect virologic response prediction) results
across the range of possible prediction cutoffs. The AUC (Area
Under the Curve) is a value between 0 and 1 that corresponds to
the probability that a randomly selected virologic success receives
a higher score than a randomly selected virologic failure. We used
the AUCs to calculate how well the systems separate the GSS
groups into those with and without undetectable viral load
(,50 copies/ml). Robust extra-sample error estimation was
obtained by 10-fold cross-validation [14]. We compared the
multiple independent runs of the 10-fold cross validation results
with a Kruskal-Wallis test. Analyses were performed with the
SPSS software package (version 15.0 for Windows, SPSS).
Results
Baseline characteristics of the study population
The baseline characteristics are shown in Table 1. We included
3131 patients in our study, of which most were male (73%), most
were infected with subtype B viruses (81.9%), and the median age
was 39 years (range 18–78). Of the 3131 patients, 476 (12.7%) had
more than one TCE, which leads to a total of 3,763 TCEs
included in the study. Of these TCEs, 2,152 had a viral load
measurement at week 12, 2,570 at week 24, and 1,083 at week 48.
TCEs were retrospectively included between 1996 and 2008. Most
TCEs (2085, 55.4%) were included between 2001 and 2004, and
fewer TCEs were included between 2005 and 2008 (1029, 27.3%)
and between 1996 and 2000 (649, 17.2%). The median HIV RNA
level of the TCEs was 4.43 log10 copies/ml [interquartile range
(IQR), 3.65–5.08], and the median CD4
+ cell count was 233 cells/
mL (IQR, 120–371 cells/mL). The most commonly given treat-
ments were lamivudine (59%), tenofovir (37%), and lopinavir
(35%). A combination of lamivudine, zidovudine, and lopinavir/r
was the most frequently given therapy combination, with a
percentage of 8%, followed by 6% for the therapy combination
lamivudine, tenofovir, and lopinavir/r.
Prevalence of mutations at baseline
The percentage of sequences having a drug resistance mutation
is shown in Figure 2. NRTI resistance associated mutations were
most frequently found with a prevalence of 62% [13]. The most
prevalent NRTI resistance mutations were M41L (27.0%), D67N
Figure 2. Drug resistance prevalences. Percentage of sequences having resistance mutations to NRTI (red), NNRTI (yellow), PI (green), and Multi
drug resistance (MDR) (blue).
doi:10.1371/journal.pone.0011505.g002
Figure 3. Total Genotypic Susceptibility Scores for ANRS, HIVdb, and Rega. Total Genotypic Susceptibility Scores were calculated using the
arithmetic sum of the individual scores given by the systems for each specific drug given in a regimen. We classified the GSS score for ANRS, HIVdb,
and Rega in the following categories: 0 to ,1, 1 to ,2, 2 to ,3, 3 to ,4, and $4. GSS scores were calculated for 3759 TCEs.
doi:10.1371/journal.pone.0011505.g003
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associated with resistance to NNRTI and PI, were detected less
frequently, in 34% and 32% of the cases, respectively. K103N
(18.6%), V181C (10.2%), and G190A (8.0%) were the most
prevalent NNRTI mutations. The PI mutations with highest
prevalences were M46IL (13.2%), V82A (9.6%), and L90M
(16.9%). The comparisons of the mutation patterns showed no
substantial differences between TCEs with a follow-up viral load at
12, 24, and 48 weeks.
Genotypic Susceptibility Score distribution
The genotypic susceptibility scores for a TCE was calculated as
the total score of genotypic susceptibility scores for all drugs in one
regimen as explained in the ‘method’ section. Figure 3 displays the
proportions of cases in each susceptibility category, according to
ANRS, HIVdb, and Rega. All systems show that at least three
active drugs were started in a large proportion of TCEs. The mean
GSS of the three systems were slightly smaller for HIVdb, with
1.9261.17, compared to Rega and ANRS, with 2.2261.09 and
2.2361.05, respectively. The unweighted Rega scores did not
differ much from the other scores with a mean of 2.1561.09.
The GSS of TCEs with longer follow-up were slightly higher
compared to TCEs with a short follow-up time (data not shown),
with baseline GSS means ranging between 1.93 and 2.23 at 12
weeks, 1.98 and 2.29 at 24 weeks, and 1.98 and 2.32 for TCEs
with viral load measurement available at 48 weeks.
Prediction of virologic outcomes
The virologic responses of all TCEs are described in Table 2.
The percentage of an undetectable viral load (,50 copies/ml) was
higher in week 24 compared to week 12. Week 48 did not show a
large increase in percentage compared to week 24. TCEs with
higher Genotypic Susceptibility Score had a higher change of
reaching an undetectable level of viral load. At 48 weeks, in more
than 70% of the TCEs with a Genotypic Susceptibility Score of
$4, the viral load became undetectable.
Adjusted odds ratios for reaching a viral load below 50 copies/
mL for each unit increase in GSS are reported in figure 4. These
predictions of the virological response were similar to the odds
ratios without adjusting for log viral load at start of therapy and
real time to viral load measurement (data not shown). At all time
points, the interpretation systems were significantly predictive of
the virological response. Odds Ratios for each unit increase of the
GSSs ranged from 1.77 (95% Confidence Intervals (CI): 1.62–
1.94), 1.87 (95%CI: 1.69–2.06), and 1.88 (95%CI: 1.70–2.08) at
12 weeks to around 1.99 (95% CI: 1.84–2.16), 2.20 (95%CI: 2.01–
2.41), and 2.16 (95%CI: 1.97–2.37) at 24 weeks for HIVdb, Rega,
and ANRS, respectively. Furthermore, the Odds Ratios for the
unweighted Rega scores were similar, ranging between 1.86 (95%
CI: 1.69–2.05) at week 12 and 2.16 (95% CI: 1.98–2.36) at week
24.
The ROC curves in figure 5 depict different cut-off points, for
the three interpretation systems. In the table below the graph, the
sensitivity, 1-specificity, and specificity are given for these cut-off
points. The sensitivity and specificity of the ROC curves for the
systems are all similar. The calculated AUCs were around 0.63 at
week 12 and 0.68 at week 24 and 48 (shown in Table 3). These
AUCs did not significantly differ among the systems (with p-values
ranging between 0.60–0.97) at all time points. The AUCs of the
unweighted Rega did not differ from the normal ANRS, HIVdb,
and Rega scores, with means of 0.63 at week 12 and 0.68 at week
24 and 48. (data not shown).
In figure 6, Kaplan-Meier curves are given, showing clear
associations between the GSS groups and the proportion of TCEs
Table 2. The viral load response and GSS groups at different
time points.
ANRS HIVdb Rega
week 12 24 48 12 24 48 12 24 48
GSS 0-,1 7.3 8.3 8.1 12.4 14.8 18.0 10.0 9.3 12.0
GSS 1-,2 23.7 30.0 33.5 28.6 39.4 41.6 19.7 26.4 27.4
GSS 2-,3 36.7 47.6 51.7 44.7 55.9 61.7 39.2 50.2 54.9
GSS 3-,4 46.2 64.4 66.7 47.1 66.4 68.1 46.0 65.0 67.2
GSS $4 47.2 69.0 74.6 45.0 68.0 72.0 47.3 65.1 72.1
The percentages of treatment-change episodes with an undetectable viral load
(,50 copies/ml) are shown for each GSS group at week 12, week 24, and week
48 for ANRS, HIVdb and Rega.
doi:10.1371/journal.pone.0011505.t002
Figure 4. Association between Genotypic Susceptibility Score and undetectable viral load. The adjusted odds ratios (ORs) with 95%
confidence intervals for RNA levels ,50 copies/ml at (A) 12 weeks, (B) 24 weeks, and (C) 48 weeks per unit increase of GSS according to ANRS, HIVdb,
and Rega. These odds ratios were adjusted for log viral load at start of therapy and real time to viral load measurement, and similar to the unadjusted
odds ratios.
doi:10.1371/journal.pone.0011505.g004
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show the highest proportion of TCEs having an undetectable viral
load. The Odds Ratios of each GSS group are given in Table 4 for
all time point measurements. In the comparison between the
different GSS groups and the GSS group of 0 to ,1, increasing
Odds Ratios were found for an increasing GSS. Odds Ratios were
higher at week 24 compared to week 12 for all GSS groups and in
all three interpretation systems, whereas the results at week 48 did
not differ much from those at week 24. Due to the low numbers of
included TCEs in GSS group $4 and at week 48, large confidence
intervals were seen in these groups. At week 24, the Odds Ratios
increased from 4.70 (95% CI: 2.57–8.60) to 26.42 (95% CI:
13.49–51.77) for ANRS, from 3.62 (95% CI: 2.56–5.13) to 13.49
(95% CI: 8.25–22.06) for HIVdb, and from 3.46 (95% CI: 2.03–
5.91) to 19.34 (10.70–34.94) for Rega.
Discussion
In this study, data from treated HIV-1 patients were modeled to
predict virological outcome comparing genotypic drug resistance
with the most commonly used interpretation systems. We used
logistic regression and AUC calculations and showed in 3,763
treatment change episodes that ANRS, HIVdb, and Rega, do not
differ in predicting virological outcomes.
Comparisons of interpretation systems have been previously
reported [9,10,15,16,17]. In this work, due to the large study
Figure 5. ROC curves for the logistic models for ANRS, HIVdb, and Rega at 12 weeks. The sensitivity, 1-specificity, and specificity are given
in the table for the cut-off points 0.5 (A), 1.5 (B), 2.5 (C), and 3.5 (D) for ANRS, HIVdb, and Rega.
doi:10.1371/journal.pone.0011505.g005
Table 3. Multiple cross-validation for calculating AUC for the
different interpretation systems.
week system AUC
* sd Kruskal-Wallis test
Chi-square p-value
Week 12 ANRS 0.629 0.05 0.280 0.597
HIVdb 0.634 0.05
Rega 0.620 0.05
Week 24 ANRS 0.677 0.04 0.143 0.705
HIVdb 0.689 0.03
Rega 0.689 0.03
Week 48 ANRS 0.671 0.06 0.001 0.970
HIVdb 0.680 0.06
Rega 0.679 0.06
All weeks ANRS 0.671 0.03 0.322 0.570
HIVdb 0.680 0.03
Rega 0.680 0.02
*AUCs (area under the receiver operating characteristic curve) were obtained from
10-fold cross-validated predictions. AUCs of 0.5 indicate that the interpretation
system is not an explanatory factor for the percentage undetectable viral load.
doi:10.1371/journal.pone.0011505.t003
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scores between patients using many different drug therapy
combinations and control for important possible confounders.
The results of our study were in agreement with previous findings
[10,16]. In addition to previous work, our study has extensively
looked at the differences between the prediction ability of the
systems at different time points. We both included short term
responses (week 12) and longer term responses (week 24 and 48).
An explanation for the findings in this study is that the systems
all make use of the same literature available on correlations
between genotypic and phenotypic analyses as well as correlations
with treatment history and clinical response.
Several studies showed small changes in genotypic susceptibility
scores between different systems. For example Ravela et al. [18],
that compared 4 different interpretation systems (including ANRS,
HIVdb, and Rega), reported a 4.4% complete discordance, with at
least 1 system assigning susceptible and another system assigning
resistant; 29.2% displayed partially discordance; and 66.4% were
complete concordant. However, in this study we found that these
differences do not have a large influence on the virological
outcome of treatment.
A possible limitation of studies comparing different interpreta-
tion systems lies in the translation of the indications from the
interpretation systems into numeric values, which are taken
arbitrarily. However, we have used the same principles used by
authors of HIV drug-resistance algorithms for calculating the
genotypic susceptibility score. Therefore we were able to compare
the three systems in the way they are used in practice. We also
used the Rega scores without the suggestions about weighting of
scores for boosted PI drugs and NNRTI. Using these unadjusted
scores did not change in GSS distributions and virological
outcome to a great extent.
Some novel drugs (etravirine, darunavir, tipranavir) were not
frequently used in our study population. Similarly, drugs
belonging to the newly approved classes, such as raltegravir
and maraviroc, were not included. Therefore, the predictive
Figure 6. Association of undetectable viral load and Genotypic Susceptibility Score over time. Kaplan Meier curves showing the
association between time to undetectable viral load and the proportion of TCEs having an undetectable viral load for the 5 Genotypic Susceptibility
Score groups for (A) ANRS (B) HIVdb and (C) Rega. Due to lost to follow-up at later viral load measurement time points, we limited the follow-up time
to 30 weeks.
doi:10.1371/journal.pone.0011505.g006
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system and we did not attempt to validate individual rules.
Continuous validations in large dataset with recent drug data will
therefore remain needed.
No restriction on therapies was performed; therefore
suboptimal regimens (fewer than three full-dose drugs) were
included. However, the group of patients receiving suboptimal
regimens was small and the same for all three interpretation
systems. Furthermore, it was previously demonstrated that
removal of suboptimal treatment reduces the accuracy of the
models [19].
Much discussion has been going on about which follow-up
period is most suitable to validate a system. Short term responses
might be more directly attributable to the antiviral drug activity
whereas longer term outcomes might be more clinically relevant
but more easily confounded by other issues such as loss in
adherence, drug discontinuations and switches [20]. In our study
less than 1/3 of all cases were left at the 48 week time point
measurement. This loss to follow up creates selection bias in this
group. Therefore, this 48-week-group may not be representative of
the whole study population. The patients, who remain on therapy
until the 48
th week after start of therapy, will do better on therapy
and will have better virological responses than patients who switch
to another therapy at earlier stages. In accordance, we found
stronger associations between interpretation systems and virolog-
ical outcomes at later time points compared to earlier time points
in the logistic regression analyses. However, in the logistic
regression that compared the different GSS groups to the GSS
group of 0 to ,1, the Odds Ratios were similar between week 24
and week 48. Therefore, week 24 may be a well suitable time point
to measure long term responses. However, confidence intervals in
week 48 were large, because of low numbers of included TCEs,
therefore creating a bias at this time-point.
In conclusion, we found that the three most common used
interpretation systems do not differ in their ability to predict
virological response. Also, when looking into different time points,
the prediction abilities between the systems were similar. Since the
overall performance is comparable, these systems might evolve
towards a more consistent scoring in the future. New break-
throughs might be needed for further improvement in genotypic
resistance test interpretation.
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